论文部分内容阅读
目的 观察诺维本(Navelbine)与顺铂、丝裂霉素联合治疗晚期(Ⅲb～Ⅳ)非小细胞肺癌的近期临床效果及其毒性作用。方法 收治Ⅲb-Ⅳ期非小细胞肺癌35例,其中男性19例,女性16例,年龄27～70岁,中位年龄59岁。其中腺癌26例,鳞癌5例,鳞腺癌4例。初治11例,复治24例。诺维本25mg-35mg/m~2,第1天与第8天各1次。顺铂80mg～100mg/m~2,分2次第2、3天。丝裂霉素6mg～8mg/m2,第1天。21天重复。结果 部分缓解(PR)13例,稳定(SD)18例,进展(PD)4例,总有效率37.14％,中位生存期7.5个月。骨髓抑制为剂量限制性毒性,其中Ⅱ～Ⅲ度为48.57％,局部静脉炎14.30％(5/35),支气管痉挛5.71％(2/35)。结论 诺维本与顺铂、丝裂霉素联合治疗晚期(Ⅲb～Ⅳ)非小细胞肺癌疗效好,毒性反应中等,可做为一线方案应用。
Objective To observe the short-term clinical efficacy and toxicity of Navelbine combined with cisplatin and mitomycin in the treatment of advanced (IIIb~IV) non-small cell lung cancer. Methods Thirty-five patients with stage IIIb-IV non-small cell lung cancer were treated, including 19 males and 16 females, aged 27 to 70 years, and median age of 59 years. There were 26 adenocarcinomas, 5 squamous cell carcinomas, and 4 squamous cell carcinomas. 11 cases were initially treated and 24 cases were retreated. Navelbine 25mg-35mg/m~2, once on the first and eighth days. Cisplatin 80mg ~ 100mg/m~2, 2nd and 3rd days. Mitomycin 6 mg to 8 mg/m2 on day 1. Repeat 21 days. Results There were 13 cases of partial remission (PR), 18 cases of stable (SD), and 4 cases of progressive (PD). The total effective rate was 37.14%. The median survival period was 7.5 months. Myelosuppression was dose-limiting toxicity, with 48.57% for II-III, 14.30% for local phlebitis (5/35), and 5.71% for bronchospasm (2/35). Conclusion The combination of Navelbine with cisplatin and mitomycin in the treatment of advanced (IIIb ~ IV) non-small cell lung cancer has good curative effect and moderate toxicity. It can be used as the first-line application.